Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil.

AIMS The aim was to compare possible effects of verapamil, as a P-glycoprotein (P-gp) inhibitor, on the pharmacokinetics of each fexofenadine enantiomer, as a P-gp substrate. METHODS Thirteen healthy Japanese volunteers (10 male and three female) were enrolled. In a randomized, two-phase, crossover design, verapamil was dosed 80 mg three times daily (with total daily doses of 240 mg) for 6 days, and on day 6, a single 120-mg dose of fexofenadine was administered along with an 80-mg dose of verapamil. Subsequently, fexofenadine was administered alone after a 2-week wash-out period. The plasma concentrations of fexofenadine enantiomers were measured up to 24 h after dosing. RESULTS During the control phase, the mean AUC(0-infinity) of S(-)- and R(+)-fexofenadine was 700 ng h(-1) ml(-1)[95% confidence interval (CI) 577, 823] and 1202 ng h(-1) ml(-1) (95% CI 1007, 1396), respectively, with a significant difference (P < 0.001). Verapamil had a greater effect on the pharmacokinetic parameters of S(-)-fexofenadine compared with those of the R(+)-enantiomer, and increased AUC(0-infinity) of S(-)-fexofenadine and R(+)-fexofenadine by 3.5-fold (95% CI of differences 1.9, 5.1; P < 0.001) and by 2.2-fold (95% CI of differences 1.7, 3.0; P < 0.001), respectively. The R/S ratio for the AUC(0-infinity) was reduced from 1.76 to 1.32 (P < 0.001) by verapamil treatments. CONCLUSION This study indicates that P-gp plays a key role in the stereoselectivity of fexofenadine pharmacokinetics, since the pharmacokinetics of fexofenadine enantiomers were altered by the P-gp inhibitor verapamil, and this effect was greater for S-fexofenadine compared with R-fexofenadine.

[1]  M. Miura,et al.  The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. , 2008, British journal of clinical pharmacology.

[2]  M. Miura,et al.  Pharmacokinetics of fexofenadine enantiomers in healthy subjects. , 2007, Chirality.

[3]  M. Miura,et al.  Determination of fexofenadine enantiomers in human plasma with high-performance liquid chromatography. , 2007, Journal of pharmaceutical and biomedical analysis.

[4]  J. Gorski,et al.  The effect of short‐ and long‐term administration of verapamil on the disposition of cytochrome P450 3A and P‐glycoprotein substrates , 2006, Clinical pharmacology and therapeutics.

[5]  N. Yasui-Furukori,et al.  Different Effects of Three Transporting Inhibitors, Verapamil, Cimetidine, and Probenecid, on Fexofenadine Pharmacokinetics , 2005, Clinical pharmacology and therapeutics.

[6]  J. Nezu,et al.  Functional Characterization of pH-Sensitive Organic Anion Transporting Polypeptide OATP-B in Human , 2004, Journal of Pharmacology and Experimental Therapeutics.

[7]  R. Kim,et al.  Organic anion‐transporting polypeptide (OATP) transporter family and drug disposition , 2003, European journal of clinical investigation.

[8]  H. Lennernäs,et al.  Multiple transport mechanisms involved in the intestinal absorption and first‐pass extraction of fexofenadine , 2003, Clinical pharmacology and therapeutics.

[9]  R. Kim.  Transporters and xenobiotic disposition. , 2002, Toxicology.

[10]  L. Benet,et al.  Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and Caco-2 cells. , 2002, Journal of pharmaceutical sciences.

[11]  D. Greenblatt,et al.  Fexofenadine Transport in Caco‐2 Cells: Inhibition with Verapamil and Ritonavir , 2002, Journal of clinical pharmacology.

[12]  P. Dawson,et al.  Fruit juices inhibit organic anion transporting polypeptide–mediated drug uptake to decrease the oral availability of fexofenadine , 2002, Clinical pharmacology and therapeutics.

[13]  B. Haehner‐Daniels,et al.  The effect of rifampin administration on the disposition of fexofenadine , 2001, Clinical pharmacology and therapeutics.

[14]  F. Sturtz,et al.  Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  M. Fromm,et al.  Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. , 2000, The Journal of pharmacology and experimental therapeutics.

[16]  B. Jarvis,et al.  Fexofenadine , 2000, Drugs.

[17]  G R Wilkinson,et al.  OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[18]  D. J. Pack,et al.  Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16 455) and its enantiomers in healthy male volunteers , 1998, Biopharmaceutics & drug disposition.

[19]  M C Willingham,et al.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[20]  T. Tsuruo,et al.  Potentiation of vincristine and Adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. , 1983, Cancer research.

[21]  T. Tsuruo,et al.  Promotion by verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug. , 1983, Cancer research.